These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 33883256)

  • 1. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
    Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer.
    Gadwa J; Bickett TE; Darragh LB; Knitz MW; Bhatia S; Piper M; Van Court B; Bhuvane S; Nguyen D; Nangia V; Kleczko EK; Nemenoff RA; Karam SD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer.
    Oweida AJ; Darragh L; Phan A; Binder D; Bhatia S; Mueller A; Court BV; Milner D; Raben D; Woessner R; Heasley L; Nemenoff R; Clambey E; Karam SD
    J Natl Cancer Inst; 2019 Dec; 111(12):1339-1349. PubMed ID: 30863843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy.
    Rutihinda C; Haroun R; Saidi NE; Ordoñez JP; Naasri S; Lévesque D; Boisvert FM; Fortier PH; Belzile M; Fradet L; Hubert-Tremblay V; Turgeon GA; Wang CS; Delage P; Rousseau É; Paquette B; Oweida AJ
    Cancer Immunol Immunother; 2023 May; 72(5):1089-1102. PubMed ID: 36326893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
    Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
    Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
    Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
    [No Abstract]   [Full Text] [Related]  

  • 10. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
    Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.
    Son CH; Bae JH; Lee HR; Shin DY; Yang K; Park YS
    J Immunother; 2015 Apr; 38(3):107-15. PubMed ID: 25751500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Batf3
    Ziblat A; Horton BL; Higgs EF; Hatogai K; Martinez A; Shapiro JW; Kim DEC; Zha Y; Sweis RF; Gajewski TF
    Cell Rep; 2024 May; 43(5):114141. PubMed ID: 38656869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Specific Antibody, Cetuximab, Enhances the
    Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
    Front Immunol; 2020; 11():591139. PubMed ID: 33281820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
    Saito S; Kono M; Nguyen HCB; Egloff AM; Messier C; Lizotte P; Paweletz C; Adkins D; Uppaluri R
    Clin Cancer Res; 2024 May; 30(9):1934-1944. PubMed ID: 38372707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
    Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.
    Bhattacharya S; Muhammad N; Steele R; Peng G; Ray RB
    Oncotarget; 2016 May; 7(22):33202-9. PubMed ID: 27120805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
    Spranger S; Dai D; Horton B; Gajewski TF
    Cancer Cell; 2017 May; 31(5):711-723.e4. PubMed ID: 28486109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Effector Phenotype of Tim-3
    Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
    Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.